期刊文献+
共找到1,724篇文章
< 1 2 87 >
每页显示 20 50 100
复方谷氨酰胺肠溶胶囊对腹泻为主型肠易激综合征的临床疗效观察 被引量:21
1
作者 苏惠 盛剑秋 +5 位作者 晨智敏 李爱琴 闫伟 余东亮 张英辉 李世荣 《胃肠病学》 2006年第10期602-604,共3页
背景:肠易激综合征(IBS)是一种常见的慢性肠功能紊乱性疾病,目前治疗方法较多,但疗效均不确切。目的:观察复方谷氨酰胺肠溶胶囊对腹泻为主型IBS的临床疗效。方法:80例腹泻为主型IBS患者随机分为2组,每组40例,分别予复方谷氨酰胺肠溶胶囊... 背景:肠易激综合征(IBS)是一种常见的慢性肠功能紊乱性疾病,目前治疗方法较多,但疗效均不确切。目的:观察复方谷氨酰胺肠溶胶囊对腹泻为主型IBS的临床疗效。方法:80例腹泻为主型IBS患者随机分为2组,每组40例,分别予复方谷氨酰胺肠溶胶囊(500mg,3次/天)和枯草杆菌、肠球菌二联活菌肠溶胶囊(500mg,3次/天),疗程2周。治疗7天和14天后询问并记录腹泻、腹痛和腹胀等症状的改善情况。结果:复方谷氨酰胺肠溶胶囊组的总有效率为85.0%,二联活菌肠溶胶囊组为72.5%,差异无统计学意义;复方谷氨酰胺肠溶胶囊治疗腹泻的疗效优于二联活菌肠溶胶囊(92.5%对60.0%,P<0.05),两组对腹痛、腹胀的疗效无统计学差异。结论:复方谷氨酰胺肠溶胶囊和二联活菌肠溶胶囊均对腹泻为主型IBS有效,但前者治疗腹泻的疗效优于后者。 展开更多
关键词 谷氨酰胺 片剂 肠衣 肠易激综合征
下载PDF
长期服用小剂量肠溶型阿司匹林对胃十二指肠黏膜损害的病例对照研究 被引量:16
2
作者 张大真 权正良 李增烈 《胃肠病学》 2006年第7期427-430,共4页
背景:长期以来,因预防或治疗需要而长期服用小剂量肠溶型阿司匹林的安全性一直受到关注。目的:观察长期服用小剂量(≤100mg/d)肠溶型阿司匹林对胃十二指肠黏膜的损害情况。方法:纳入5年中服用小剂量肠溶型阿司匹林超过3个月且既往无消... 背景:长期以来,因预防或治疗需要而长期服用小剂量肠溶型阿司匹林的安全性一直受到关注。目的:观察长期服用小剂量(≤100mg/d)肠溶型阿司匹林对胃十二指肠黏膜的损害情况。方法:纳入5年中服用小剂量肠溶型阿司匹林超过3个月且既往无消化性溃疡和消化道出血史、胃镜检查前2周未服用其他非甾体抗炎药(NSAID)、抑酸剂、抗生素、铋剂等药物、未接受过幽门螺杆菌(H.pylori)根除治疗而具有上消化道症状者行内镜检查。结果:92例入选患者中,40例(43.5%)发现轻度胃十二指肠黏膜损害,但无一例形成黏膜溃疡。黏膜损害组和无黏膜损害组患者的年龄、性别、吸烟、阿司匹林日平均用量和常见消化不良症状均无显著差异(P>0.05)。黏膜损害组的H.pylori感染率显著高于无黏膜损害组(P<0.05)。尽管吸烟、年龄的分层分析未能证实H.pylori感染在黏膜损害中的重要作用,但H.pylori的感染程度与黏膜损害程度呈正相关(rs=0.308,P<0.05)。结论:长期服用小剂量肠溶型阿司匹林可引起轻度胃十二指肠黏膜损害,H.pylori感染、吸烟和年龄均是危险因素,但H.pylori感染的危险性可能更大。 展开更多
关键词 阿司匹林 片剂 肠衣 胃黏膜 肠黏膜 损伤
下载PDF
Oral fibrinogen-depleting agent lumbrokinase for secondary ischemic stroke prevention: results from a multicenter, randomized, parallel- group and controlled clinical trial 被引量:13
3
作者 Cao Yong-jun Zhang Xia +11 位作者 Wang Wan-hua Zhai Wan-qing Qian Ju-fen Wang Jian-sheng Chen Jun You Nian-xing Zhao Zhong Wu Qiu-yi Xu Yuan Yuan Lei Li Rui-xia Liu Chun-feng 《Chinese Medical Journal》 SCIE CAS CSCD 2013年第21期4060-4065,共6页
Background Elevated fibrinogen (Fg) level is a known risk factor for ischemic stroke. There are few clinical trials on oral fibrinogen-depleting therapies for secondary ischemic stroke prevention. We aimed to assess... Background Elevated fibrinogen (Fg) level is a known risk factor for ischemic stroke. There are few clinical trials on oral fibrinogen-depleting therapies for secondary ischemic stroke prevention. We aimed to assess the effects of one-year therapy with oral lumbrokinase enteric-coated capsules on secondary ischemic stroke prevention. 展开更多
关键词 ischemic stroke lumbrokinase enteric-coated capsules FIBRINOGEN carotid atherosclerosis
原文传递
褐藻胶植物肠溶硬胶囊的制备技术 被引量:12
4
作者 张东 高昕 +2 位作者 许加超 刘天中 张朝晖 《食品工业科技》 CAS CSCD 北大核心 2011年第3期321-323,共3页
对褐藻胶植物肠溶硬胶囊的制备工艺进行了研究,并对最佳工艺条件下制备得到的胶囊进行成囊性、脆碎性、崩解时限、灼烧残渣等理化指标的测定。根据传统明胶硬胶囊的制备工艺及褐藻胶凝胶特性,实验确定褐藻胶肠溶硬胶囊工艺流程为溶胶、... 对褐藻胶植物肠溶硬胶囊的制备工艺进行了研究,并对最佳工艺条件下制备得到的胶囊进行成囊性、脆碎性、崩解时限、灼烧残渣等理化指标的测定。根据传统明胶硬胶囊的制备工艺及褐藻胶凝胶特性,实验确定褐藻胶肠溶硬胶囊工艺流程为溶胶、制胚、钙化、干燥、拔壳等,其中钙化过程中使用CaCl2溶液对褐藻胶胶囊毛胚进行直接钙化,使其形成酸不溶性凝胶,从而使褐藻胶胶囊具备肠溶性。通过单因素实验和正交实验确定最佳制备工艺为:以8cP褐藻胶为原料,胶液浓度12%,甘油添加量3%,2%CaCl2溶液钙化15s,胶囊含水量为15%。制备出胶囊的成囊性、脆碎性均符合药典对硬胶囊的要求,且在人工胃液中2h不溶,肠液中崩解时限为43±1min,完全符合药典对肠溶胶囊的要求。 展开更多
关键词 硬胶囊 褐藻胶 正交实验 肠溶
下载PDF
Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients 被引量:8
5
作者 QIU Kui TIAN Hui +7 位作者 WANG Wei HU Xiao-peng LI Xiao-bei GONG Li-li LUO Wei LIU Li-hong ZHANG Xiao-dong YIN Hang 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第23期4226-4232,共7页
Background Mycophenolic acid (MPA) as an anti-proliferative immune-suppressive agent is used in the majority of immunosuppressive regimens in solid organ transplantation. This study aimed to investigate the pharmaco... Background Mycophenolic acid (MPA) as an anti-proliferative immune-suppressive agent is used in the majority of immunosuppressive regimens in solid organ transplantation. This study aimed to investigate the pharmacokinetic (PK) characteristics of enteric-coated mycophenolate sodium (EC-MPS) and area under the curve (AUC) from 0 to 12 hours with limited sampling strategies (LSSs) in Chinese renal transplant recipients. Methods This study was conducted in 10 Chinese renal transplant patients receiving living donor and treated with EC-MPS, cyclosporine, and corticosteroids. MPA concentrations were measured by enzyme multiplied immunoassay technique (EMIT). Whole 12-hour PK profiles were obtained on Day 4 after operation. LSSs with jackknife technique, multiple stepwise regression analysis, and Bland-Altman analysis were developed to estimate MPAAUC. Results The mean maximum plasma concentration, the mean time for it to reach peak (Tmax), and the mean MPA AUC were (11.38±2.49) mg/L, (4.85±3.32) hours, and (63.19±13.54) mg.h.L1, respectively. Among the 10 profiles, MPA AUC of four patients was significantly higher than that of the other six patients, and the corresponding Tmax was significantly longer than that of the other six patients. No patient exhibited a second peak caused by enterohepatic recirculation. The best models were as follows: 27.46+0.94C3+3.24C8+2.81C10 (f2=0.972), which was used to predict AUC of fast metabolizer with a mean prediction error (MPE) of -0.21% and a mean absolute prediction error (MAE) of 2.59%; 36.65+3.08Ce+5.30C10-4.04C12 (r2=0.992), which was used to predict AUC of slow metabolizer with a MPE of 0.58% and a MAE of 1.95%. Conclusions The PKs of EC-MPS had a high variability among Chinese renal transplant recipients. The preliminary PK data indicated the existence of slow and fast metabolizer. These findings may be associated with the enterohepatic rec.irculation. 展开更多
关键词 enteric-coated mycophenolate sodium PHARMACOKINETICS limited sampling strategy Chinese renal transplant recipients
原文传递
Clinical Effect of Ilaprazole Enteric-Coated Tablets in Patients with Peptic Ulcer
6
作者 Fanghui Chen 《Journal of Biosciences and Medicines》 2024年第9期155-160,共6页
Objective: To discuss the actual effect of ilaprazole enteric-coated tablets in the treatment of peptic ulcer patients. Methods: 200 peptic ulcer patients who received treatment from January to December 2023 were sele... Objective: To discuss the actual effect of ilaprazole enteric-coated tablets in the treatment of peptic ulcer patients. Methods: 200 peptic ulcer patients who received treatment from January to December 2023 were selected as the study sample, and all patients were randomly and evenly divided into the study group (n = 100) and the control group (n = 100), and the serum inflammatory factors and the disappearance time of symptoms were compared. Results: After treatment, the serum inflammatory factors in the observation group were better than those in the control group, and the time of belching and burning sensation in the observation group was shorter than that in the control group, all of which were statistically significant (P Conclusion: Ilaprazole enteric-coated tablets in the treatment of peptic ulcer have a good effect and can effectively improve the symptoms of patients with clinical signs, with reference significance. 展开更多
关键词 Ilaprazole enteric-coated Tablets Peptic Ulcer SYMPTOMS
下载PDF
Analysis of the Therapeutic Effect of Clopidogrel Bisulfate Tablets + Aspirin Enteric-Coated Tablets on Acute Myocardial Infarction
7
作者 Yiru Chen 《Journal of Clinical and Nursing Research》 2024年第6期290-294,共5页
Objective:To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction(AMI)patients.Methods:The study period was from Janu... Objective:To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction(AMI)patients.Methods:The study period was from January 2020 to December 2023,the sample source was 82 AMI patients admitted to our hospital,grouped into an observation group(n=41)and a control group(n=41)by the numerical table method.The patients in the control group were treated with aspirin enteric-coated tablets,and the patients in the observation group were treated with aspirin enteric-coated tablets combined with clopidogrel bisulfate.The clinical efficacy,coagulation indexes,and the incidence of cardiovascular adverse events between the two groups were compared.Results:The clinical efficacy of the observation group was higher than that of the control group(P<0.05);the platelet aggregation rate(PAR)of the observation group was lower than that of the con-trol group after treatment(P<0.05),and there was no significant difference in the prothrombin time(PT)and activated partial thromboplastin time(APTT)between the two groups(P>0.05).The incidence of cardiovascular adverse events in the observation group was lower than that of the control group(P<0.05).Conclusion:The treatment effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on AMI patients is remarkable.It reduces the PAR and the incidence of cardiovascular adverse events,so this treatment method should be popularized. 展开更多
关键词 Clopidogrel bisulfate Aspirin enteric-coated tablets Acute myocardial infarction
下载PDF
胰岛素肠溶胶丸人体药代动力学、药效动力学及生物利用度研究 被引量:6
8
作者 赵维纲 王姮 +1 位作者 孙琦 董亚秀 《中华内科杂志》 CAS CSCD 北大核心 2007年第6期462-465,共4页
目的以正规胰岛素皮下注射制剂为参比,进行胰岛素肠溶胶丸人体药代动力学、药效动力学及相对生物利用度研究。方法 20例健康受试者,男14例,女6例,年龄21~41(28.6±5.2)岁,BMI 18.0~22.0(21.2±1.1)kg/m^2,在正常血糖葡萄糖钳... 目的以正规胰岛素皮下注射制剂为参比,进行胰岛素肠溶胶丸人体药代动力学、药效动力学及相对生物利用度研究。方法 20例健康受试者,男14例,女6例,年龄21~41(28.6±5.2)岁,BMI 18.0~22.0(21.2±1.1)kg/m^2,在正常血糖葡萄糖钳夹技术平台上,按随机顺序分别接受受试制剂(50 IU)和参比制剂(15 IU)两次试验。每个试验日经2h 平衡后给药,采29个时点血样测血清胰岛素水平,同时记录12h 中每5分钟的葡萄糖输注率,以计算药代动力学和药效动力学参数。结果受试制剂与参比制剂的血药浓度峰值分别为(22.1±8.0)mIU/L 和(118.6±25.2)mIU/L,达峰时间分别为(255.8±142.2)min 和(115.5±43.4)min。葡萄糖处置率峰值(GIRmax)分别为(3.56±0.85)mg·kg^(-1)·min^(-1)和(4.87±1.26)mg·kg^(-1)·min^(-1),GIRmax 达峰时间分别为(166.3±75.9)min 和(148.0±40.8)min。受试制剂相对生物利用度为(7.42±3.25)%,相对有效性为(24.78±0.08)%。结论胰岛素肠溶胶丸可经胃肠道吸收入血,相对生物利用度与相对有效性差别大,充分体现了口服胰岛素制剂模拟内源胰岛素分泌生理过程所带来的益处。其药代、药效特点为进一步临床研究提供可靠的依据。 展开更多
关键词 胰岛素 胶囊 肠溶 葡萄糖钳制技术 药代动力学 生物利用度
原文传递
海藻酸钠-壳聚糖包裹制备肠溶性乳糖酶胶囊的研究 被引量:5
9
作者 李妍昕 王建刚 《解放军医药杂志》 CAS 2013年第11期71-75,共5页
目的探讨海藻酸钠-壳聚糖包裹制备肠溶性乳糖酶胶囊的方法。方法通过单因子实验探讨海藻酸钠浓度、壳聚糖浓度和氯化钙浓度对微胶囊保护乳糖酶活性的影响,并采用响应面法对制备工艺的操作参数进行优化。结果海藻酸钠浓度为1.8667%、壳... 目的探讨海藻酸钠-壳聚糖包裹制备肠溶性乳糖酶胶囊的方法。方法通过单因子实验探讨海藻酸钠浓度、壳聚糖浓度和氯化钙浓度对微胶囊保护乳糖酶活性的影响,并采用响应面法对制备工艺的操作参数进行优化。结果海藻酸钠浓度为1.8667%、壳聚糖浓度为0.4319%、氯化钙浓度为0.9412%时,制备的肠溶性乳糖酶胶囊在人工模拟胃液中对乳糖酶有很好的保护作用,而且在人工模拟肠液中2 h可以完全破囊。结论海藻酸钠-壳聚糖包裹制备肠溶性乳糖酶胶囊具有很好的过胃保护作用。 展开更多
关键词 海藻酸钠 壳聚糖 胶囊 肠溶 乳糖酶
下载PDF
Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipients 被引量:3
10
作者 Jun Zhang Mengmeng Jia +5 位作者 Lihua Zuo Na Li Yonggang Luo Zhi Sun Xiaojian Zhang Zhenfeng Zhu 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2017年第3期347-352,共6页
The aim of the research was to investigate the pharmacokinetics(PK) of enteric-coated mycophenolate sodium(EC-MPS) by quantification of the active metabolite of mycophenolic acid(MPA)after multiple escalating oral dos... The aim of the research was to investigate the pharmacokinetics(PK) of enteric-coated mycophenolate sodium(EC-MPS) by quantification of the active metabolite of mycophenolic acid(MPA)after multiple escalating oral doses in Han kidney transplant recipients. A total of 28 Han postoperative kidney transplant recipients were given a multiple-dose of 540, 720 or 900 mg of EC-MPS two times a day in combination with tacrolimus for 6 days. Blood specimens were collected at each time point from0 to 12 h after EC-MPS administration. MPA plasma concentrations were measured by UPLC–UV. The relationship between the EC-MPS dose and its PK parameters was assessed. In the range from 540 to900 mg, C_(max) and AUC_(0–12h) did not increase with dose escalation. The AUC_(0–12h), C_(max), C_0 and T_(max) for the 540 720 and 900 mg doses were not significantly different, respectively(P 40.05). AUC_0–12 h and C_(max) were increased less than proportionally with increasing EC-MPS dose levels. Inter-individual variability in AUC_(0–12h), C_(max) and C_0 were considerable. Nonlinear PK relationships were found from the doses of 540–900 mg of EC-MPS. 展开更多
关键词 enteric-coated Mycophenolate sodium Mycophenolic acid Nonlinear dynamics Kidney transplantation PHARMACOKINETICS UPLC-UV Human plasma
原文传递
纳米碳酸钙肠溶生物黏附片的制备工艺研究 被引量:4
11
作者 魏科达 徐幸民 +1 位作者 方平飞 赵绪元 《中国新药杂志》 CAS CSCD 北大核心 2010年第14期1275-1280,共6页
目的:研究纳米碳酸钙肠溶生物黏附片(NCaEBT)的制备工艺。方法:片芯处方筛选以HPMCK4M和CP 940的用量为考察因素,以Ca2+在1,4 h的累积释放度和黏附力为指标,采用星点设计-效应面优化法,确定片芯优化处方;对优化处方下制备的NCaEBT片芯... 目的:研究纳米碳酸钙肠溶生物黏附片(NCaEBT)的制备工艺。方法:片芯处方筛选以HPMCK4M和CP 940的用量为考察因素,以Ca2+在1,4 h的累积释放度和黏附力为指标,采用星点设计-效应面优化法,确定片芯优化处方;对优化处方下制备的NCaEBT片芯以丙烯酸树脂Eudragit L100-55为肠溶液进行肠溶包衣,考察肠溶衣增重对NCaEBT的影响。结果:片芯处方筛选时以多元线性方程拟合的效果为佳,且具有较高的可信度,优化处方为片芯中HPMC K4M和CP 940的含量分别为15和27.5 mg,肠溶衣增重为片芯的10%。结论:本课题研制的NCaEBT体外试验能够实现肠定位、生物黏附和缓慢释放的特征,可用于开发成为驱铅治疗药物。 展开更多
关键词 纳米碳酸钙 驱铅 肠溶 生物黏附 星点设计-效应面法
原文传递
参芎葡萄糖注射液联合胰激肽原酶肠溶片治疗早期糖尿病肾病的临床疗效 被引量:2
12
作者 徐艳艳 李艳浓 +1 位作者 杨琦 丁红 《医学临床研究》 CAS 2015年第8期1522-1524,共3页
【目的】探讨参芎葡萄糖注射液联合胰激肽原酶肠溶片治疗早期糖尿病肾病的临床疗效。【方法】将2013年1月至2014年12月于中国医科大学附属第四医院肾内科住院治疗的72例糖尿病肾脏病患者随机分为对照组和治疗组,每组36例,其中对照组采... 【目的】探讨参芎葡萄糖注射液联合胰激肽原酶肠溶片治疗早期糖尿病肾病的临床疗效。【方法】将2013年1月至2014年12月于中国医科大学附属第四医院肾内科住院治疗的72例糖尿病肾脏病患者随机分为对照组和治疗组,每组36例,其中对照组采用常规治疗方法和参芎葡萄糖注射液,治疗组在对照组基础上加用胰激肽原酶肠溶片治疗,3个月后,评价两组的血清肌酐(SCr)、尿素氮(BUN)、尿白蛋白排泄率(UAER)等改变情况及进行两组临床疗效的比较。【结果】两组治疗后 UAER 较治疗前明显下降,且差异性有显著性(P <0.05);治疗组与对照组相比改善更为明显,且两组相比较差异性有显著性(P <0.05)。两组SCr,BUN 治疗前后相比较差异均无显著性(P>0.05)。治疗组总有效率为94.4%,明显高于对照组(83.3%),且两组比较差异有显著性(P <0.05)。【结论】参芎葡萄糖注射液联合胰激肽原酶肠溶片可减少糖尿病肾脏疾病患者的尿白蛋白排出,减轻肾损害,保护肾功能,延缓病变进展。 展开更多
关键词 川芎/治疗应用 葡萄糖/治疗应用 人参/治疗应用 注射剂 片剂 肠衣 糖尿病肾病/药物疗法 胰激肽/投药和剂量
下载PDF
肠溶多单元微丸片的研究进展 被引量:2
13
作者 颜东 孙倩倩 张林 《食品与药品》 CAS 2016年第1期61-64,共4页
多单元肠溶微丸片的工艺复杂性限制了其广泛应用。本文通过介绍肠溶多单元微丸片的制备工艺,结合近年国内外资料,对肠溶微丸片的研究及应用进行综述。
关键词 肠溶 多单元 微丸片
下载PDF
肠溶包衣乳糖酶纳米微囊的制备及稳定性研究 被引量:2
14
作者 贺红军 孔保华 +1 位作者 夏娟 姜竹茂 《食品工业科技》 CAS CSCD 北大核心 2011年第5期323-327,共5页
研制一种在胃和肠液中对乳糖酶具有保护作用的口服制剂。采用复乳法制备了肠溶包衣乳糖酶纳米微囊,对其理化性质进行了评价;研究了制备过程中影响乳糖酶活性的主要因素,并采取了一定的保护策略;对微囊化的乳糖酶在人工胃液和人工肠液中... 研制一种在胃和肠液中对乳糖酶具有保护作用的口服制剂。采用复乳法制备了肠溶包衣乳糖酶纳米微囊,对其理化性质进行了评价;研究了制备过程中影响乳糖酶活性的主要因素,并采取了一定的保护策略;对微囊化的乳糖酶在人工胃液和人工肠液中的稳定性进行了考察。结果表明,超声强度越大,活性损失越多;在二氯甲烷中引入乙酸乙酯(体积比为1∶1),复乳化采用高压均质,有利于保护乳糖酶的活性。在内水相添加牛血清白蛋白、聚乙烯醇和聚乙二醇400等保护剂,可有效提高乳糖酶的活性。制备的肠溶包衣乳糖酶纳米微囊在人工胃液中2h乳糖酶剩余活性为88.97%,在含胰酶的人工肠液中6h,其活性保留可达95%以上,有望成为乳糖酶口服制剂的有效剂型。 展开更多
关键词 乳糖不耐受症 肠溶包衣 乳糖酶 纳米微囊 稳定性
下载PDF
Effect of Weikang Capsule(胃康胶囊)on Aspirin-Related Gastric and Small Intestinal Mucosal Injury 被引量:2
15
作者 DU Lin GAO Feng ZHANG Jie 《Chinese Journal of Integrative Medicine》 SCIE CAS CSCD 2021年第8期621-625,共5页
Objective To investigate the effects of Weikang Capsule(胃康胶囊,WKC)on aspirin-related gastric and small intestinal mucosal injury by magnetically controlled capsule endoscopy(MCCE).Methods Patients taking enteric-co... Objective To investigate the effects of Weikang Capsule(胃康胶囊,WKC)on aspirin-related gastric and small intestinal mucosal injury by magnetically controlled capsule endoscopy(MCCE).Methods Patients taking enteric-coated aspirin aged 40-75 years were enrolled in Beijing Anzhen Hospital,Capital Medical University from January 2019 to December 2019.The patients continued taking aspirin Tablet(100 mg per day)and underwent MCCE before and after 1-month combined treatment with WKC(0.9 g per time orally,3 times per day).The gastrointestinal symptom score,gastric Lanza score,the duodenal,jejunal and ileal mucosal injury scores were used to evaluate the gastrointestinal injury before and after treatment.Adverse events including nausea,vomiting,abdominal pain,abdominal distension,abdominal discomfort,dizziness,or headache during MCCE and combined treatment were observed and recorded.Results Twenty-two patients(male/female,13/9)taking enteric-coated aspirin aged 59.5±11.3 years with a duration of aspirin use of 28.0(1.0,48.0)months were recruited.Compared with pre-treatment,the gastrointestinal symptom rating scale scores,gastric Lanza scores,and duodenal mucosal injury scores were significantly reduced after 1-month WKC treatment(P<0.05),and jejunal and ileal mucosal injury scores showed no obvious change.No adverse events occurred during the trial.Conclusions WKC can alleviate gastrointestinal symptoms,as well as gastric and duodenal mucosal injuries,in patients taking enteric-coated aspirin;it does not aggravate jejunal or ileal mucosal injury,which may be an effective alternative for these patients(Clinical trial registry No.ChiCTR1900025451). 展开更多
关键词 Weikang Capsule magnetically controlled capsule endoscopy enteric-coated aspirin gastric mucosal injury small intestinal mucosal injury Chinese medicine
原文传递
Gradient high performance liquid chromatography method for simultaneous determination of ilaprazole and its related impurities in commercial tablets 被引量:2
16
作者 Shang Wang Dong Zhang +3 位作者 Yingli Wang Xiaohong Liu Yan Liu Lu Xu 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2015年第2期146-151,共6页
A methodology(HPLC)proposed in this paper for simultaneously quantitative determination of ilaprazole and its related impurities in commercial tablets was developed and validated.The chromatographic separation was car... A methodology(HPLC)proposed in this paper for simultaneously quantitative determination of ilaprazole and its related impurities in commercial tablets was developed and validated.The chromatographic separation was carried out by gradient elution using an Agilent C8 column(4.6 mm×250 mm,5 mm)which was maintained at 25℃.The mobile phase composed of solvent A(methanol)and solvent B(solution consisting 0.02 mmol/l monopotassium phosphate and 0.025 mmol/l sodium hydroxide)was at a flow rate of 1.0 ml/min.The samples were detected and quantified at 237 nm using an ultraviolet absorbance detector.Calibration curves of all analytes from 0.5 to 3.5 mg/ml were good linearity(r≥0.9990)and recovery was greater than 99.5% for each analyte.The lower limit of detection(LLOD)and quantification(LOQ)of this analytical method were 10 ng/ml and 25 ng/ml for all impurities,respectively.The stress studies indicated that the degradation products could not interfere with the detection of ilaprazole and its related impurities and the assay can thus be considered stability-indicating.The method precisions were in the range of 0.41-1.21 while the instrument precisions were in the range of 0.38-0.95 in terms of peak area RSD% for all impurities,respectively.This method is considered stabilityindicating and is applicable for accurate and simultaneous measuring of the ilaprazole and its related impurities in commercial enteric-coated tablets. 展开更多
关键词 Ilaprazole enteric-coated tablets Related impurities HPLC Validation
下载PDF
超临界流体制备BSA包衣微丸及释药特性 被引量:1
17
作者 肖菊香 马晓文 +1 位作者 莫炜 宋后燕 《复旦学报(医学版)》 CAS CSCD 北大核心 2008年第3期380-383,共4页
目的采用自行设计的CO2超临界流体(supercritical carbon dioxide,ScCO2)包衣设备研究肠溶包衣参数,为开发蛋白质及多肽的口服制剂提供工艺基础。方法以载牛血清白蛋白(bovine serumalbumin,BSA)颗粒为微丸核心,以EUDRAGIT L100-55作为p... 目的采用自行设计的CO2超临界流体(supercritical carbon dioxide,ScCO2)包衣设备研究肠溶包衣参数,为开发蛋白质及多肽的口服制剂提供工艺基础。方法以载牛血清白蛋白(bovine serumalbumin,BSA)颗粒为微丸核心,以EUDRAGIT L100-55作为pH敏感的肠溶包衣材料,采用正交表研究压力、温度、增塑剂和包衣持续时间等不同的工艺参数组合,并考察肠溶包衣微丸的形态学和体外释放特性,以选择最优的二氧化碳超临界流体包衣工艺。结果压力为20MPa、温度为35℃、使用40%增塑剂的条件下包衣30min,所得BSA微丸在模拟胃液中释放量小于5%,在模拟肠液中迅速释放,符合肠溶包衣的要求。结论得到了通过ScCO2制备肠溶微丸的最优参数组合,为二氧化碳超临界流体包衣的进一步研究提供了基础。 展开更多
关键词 二氧化碳超临界 蛋白质 肠溶包衣
下载PDF
阿司匹林肠溶片的临床应用及其质量控制 被引量:1
18
作者 王艳玲 《中国中医药咨讯》 2009年第6期13-14,共2页
对阿司匹林肠溶片的临床应用进行了综述,简要概述了我公司对小剂量阿司匹林肠溶片工艺改进后的质量情况。
关键词 阿司匹林 肠溶 应用 游离水杨酸
下载PDF
雷贝拉唑钠肠溶胶囊处方研究及稳定性考察 被引量:1
19
作者 陈丹秋 《安徽医药》 CAS 2016年第6期1061-1064,共4页
目的筛选雷贝拉唑钠肠溶胶囊处方并考察其稳定性。方法采用挤出滚圆和流化床包衣工艺制备雷贝拉唑钠肠溶微丸,采用L9(34)正交试验设计进行载药微丸处方优化,按选定的处方制备微丸,进行隔离层和肠溶层包衣,包衣后将微丸灌装胶囊,制成10 m... 目的筛选雷贝拉唑钠肠溶胶囊处方并考察其稳定性。方法采用挤出滚圆和流化床包衣工艺制备雷贝拉唑钠肠溶微丸,采用L9(34)正交试验设计进行载药微丸处方优化,按选定的处方制备微丸,进行隔离层和肠溶层包衣,包衣后将微丸灌装胶囊,制成10 mg规格,对制备的胶囊进行加速试验确定其稳定性。结果制备的雷贝拉唑钠肠溶胶囊批间重现性好,加速条件下质量稳定,稳定性较好。结论该工艺简单可行,样品稳定性良好,可作为雷贝拉唑钠肠溶胶囊的制备工艺。 展开更多
关键词 胶囊 肠溶 药物稳定性 雷贝拉唑
下载PDF
Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma 被引量:1
20
作者 Toru Ishikawa 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第18期2797-2801,共5页
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, including Japan. Although the development of imaging modalities has made the early diagnosis of HCC possible, surgically resectable case... Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, including Japan. Although the development of imaging modalities has made the early diagnosis of HCC possible, surgically resectable cases are relatively uncommon because of hepatic function reserve and/or an advanced stage at presentation. Several modalities, such as transcatheter arterial chemoembolization, percutaneous ethanol injection, microwave coagulation therapy and radiofrequency ablation are reportedly useful in treating patients with non-resectable disease. However, unfortunately, many HCC patients have tumor recurrence. The overall prognosis of patients with HCC is very poor, and treatment of the advanced form is still problematic. In this article, we review the clinical efficacy and toxicity of enteric-coated tegafur/uracil in the treatment of patients with advanced non-resectable HCC. 展开更多
关键词 Advanced hepatocellular carcinoma Tumor dormancy enteric-coated tegafur/uracil CHEMOTHERAPY Portal vein tumor thrombus Lung metastasis
下载PDF
上一页 1 2 87 下一页 到第
使用帮助 返回顶部